NICE does not recommend Besponsa (inotuzumab ozogamicin) to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.- Pfizer
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Pfizer’s Besponsa (inotuzumab ozogamicin) to treat patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).
NICE concludes that evidence from clinical trials showed no survival benefit from Besponsa compared to current treatment, but NICE accepted that more people who were treated with the drug were able to subsequently have a stem cell transplant and go into remission than those on standard care. Because of the “highly uncertain” survival benefits, the incremental cost effectiveness ratio (ICER) was over £100,000 per QALY for Besponsa, which is substantially higher than the range considered cost effective for routine use in the NHS.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).